ASP Isotopes Inc. Stock

Equities

ASPI

US00218A1051

Pharmaceuticals

End-of-day quote Nasdaq 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
3.44 USD +1.78% Intraday chart for ASP Isotopes Inc. +9.90% +92.18%
Sales 2024 * 11.65M Sales 2025 * 15.74M Capitalization 157M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 13.5 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 9.98 x
P/E ratio 2024 *
-29.2 x
P/E ratio 2025 *
-45.9 x
Employees 76
Yield 2024 *
-
Yield 2025 *
-
Free-Float 49.83%
More Fundamentals * Assessed data
Dynamic Chart
ASP Isotopes Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Power Producers Gain as Defensive Play -- Utilities Roundup DJ
ASP Isotopes Inc. Enters into A Contract with U.S.-Based Small Modular Reactor for Project Focused on Engineering Design and Planning for Enrichment Facility for the Production of Advanced Nuclear Fuels CI
ASP Isotopes Inc. Enters into Purchase Agreement with A Leading Semiconductor Company for the Supply of Highly Enriched Electronic Gases CI
ASP Isotopes Inc. announced that it expects to receive $20 million in funding CI
ASP Isotopes Inc. agreed to Spin-Off Quantum Leap Energy LLC. CI
ASP Isotopes Inc. Announces Board Changes CI
ASP Isotopes Inc. Commences Construction of Its Third Isotopes in South Africa CI
Asp Isotopes Inc. Enters into Memorandum of Understanding with Second Us-Based Small Modular Reactor Company to Supply High Assay Low Enriched Uranium CI
ASP Isotopes Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ASP Isotopes Inc. acquired 51% stake in Pet Labs Pharmaceuticals Proprietary Limited from Nucleonics Imaging Proprietary Limited for $2 million. CI
ASP Isotopes Inc. agreed to acquire 51% stake in Pet Labs Pharmaceuticals Proprietary Limited from Nucleonics Imaging Proprietary Limited for $2 million. CI
ASP Isotopes Inc. announced that it has received $9.129495 million in funding from Tees River Critical Resources Fund Limited CI
ASP Isotopes Inc. Announces Executive Changes CI
ASP Isotopes Inc. announced that it expects to receive $9.129495 million in funding from Tees River Critical Resources Fund Limited CI
More news
1 day+1.78%
1 week+9.90%
Current month-16.71%
1 month-16.71%
3 months+46.38%
6 months+237.25%
Current year+92.18%
More quotes
1 week
3.12
Extreme 3.12
3.53
1 month
2.91
Extreme 2.91
4.34
Current year
1.65
Extreme 1.65
4.97
1 year
0.28
Extreme 0.28
4.97
3 years
0.28
Extreme 0.28
4.97
5 years
0.28
Extreme 0.28
4.97
10 years
0.28
Extreme 0.28
4.97
More quotes
Managers TitleAgeSince
Founder 48 21-09-12
Chief Executive Officer 48 21-09-12
Chief Tech/Sci/R&D Officer 64 21-12-31
Members of the board TitleAgeSince
Director/Board Member 65 21-09-30
Chief Executive Officer 48 21-09-12
Director/Board Member 59 21-09-30
More insiders
Date Price Change Volume
24-04-29 3.21 -6.69% 506,791
24-04-26 3.44 +1.78% 719,042
24-04-25 3.38 +1.20% 435,368
24-04-24 3.34 +4.37% 455,744
24-04-23 3.2 +2.24% 622,467

End-of-day quote Nasdaq, April 25, 2024

More quotes
ASP Isotopes Inc. is a pre-commercial stage advanced materials company. The Company is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100 and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.21 USD
Average target price
4.25 USD
Spread / Average Target
+32.40%
Consensus

Annual profits - Rate of surprise